Trial Profile

A Phase 1, Study of VX-828 in Healthy Subjects and in Subjects With Cystic Fibrosis

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 13 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Deutivacaftor (Primary) ; Ivacaftor/tezacaftor (Primary) ; VX 118 (Primary) ; VX 828 (Primary) ; Itraconazole; Midazolam
Indications Cystic fibrosis
Focus Adverse reactions; Pharmacokinetics; Proof of concept
Sponsors Vertex Pharmaceuticals

Most Recent Events

10 Aug 2026 Status changed from active, no longer recruiting to completed.
03 Aug 2026 According to a Vertex Pharmaceuticals media release, dosing has been completed in this study and company is on track to share results in the second half of 2026.
26 May 2026 Planned End Date changed from 23 Apr 2026 to 16 Jul 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com